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Calcium channel blockers arc now considered the agents of 
choice for the therapy of vasospastic angina (I-14). Over the 
past 10 to IS years. the efficacv of these arents has been well 
documented by oomerous sto&es, inclod& several mndom- 
ized controlled trials (I-14). The hrst generation of calcium 
channel antagonists, +‘edipivz verapamil and diltiazem. 
bad comparable &;ts when appropriate doses were used 
(6.7). In view of the relatiwly short half-life of these drugs, 
all prolocds utilized regimens :oosisting of multiple daily 
doses. Nicxdipine, a second-generation calcium channel 
blocker. has also been repotted (15) to be effective in vases- 
pastic angina when given in multiple doseslday. Newer sus- 
tained release or loyactiog formulations of the initial three 
calcium antagonists have oow been developed LO improve 
patient compliance (16-18). However. we rue not aware of any 
data regarding the place of these fonmdaions in the treatmem 
of coronary artery spasm. The correttt study was de&ted to 
assess the efficacy and safety of a second-generation calcium 
channel blocker. amkxlipine. which is recommended as aonce 
daily agent (19.20) in view of its loog half-lie. 
Metho& 
Study patients. Recruitment for this study was performed 
at i5 participating centers To he included in the study. the 
patients had to havea history ofrest angina withooeormore 
of the following criteria: I) at least one or more episodes of 
chest pain at rest associated with reversible electmcardio- 
graphic (ECG) ST segment elevation in the absence of 
myocardial infarction; 2) spontaneous or erganovine- 
in&cd coronary artery spasm (producing ~70% narrowing 
of coronary lumen diameter do& angiography) associated 
with chest pain or ischemic ST segment changes. or hoth: 
1366 CHAHlNE ET AL. 
Ah,LOD,P,NE Iti “AsosPASTIC ANGlNA 
Figure 1. Flow diagram of the study design. During the single-blind 
run-in period. all padents received placebo. The exact duration of 
this period was determined by the frequency of angina, episode,. 
Randomized double-blind treatment consisted of 4-week parallel 
docble-blind treatmenl in parallel balanced groups. 1 
and 3) ergonovine-induced reversible perfusion defect doc- 
umented by thallium-201 scintigraphy. 
Criteria I) and 3) were used usually in patients with 
documentation of angiographically normal coronary arteries. 
Patients were also required to have evidence of disease 
activity manifested by the occurrence of at least three 
episodes of anginaat rest during a run-in single-blind placebo 
period of 3 to 14 days. 
Exclusion criteria included: I) women of chiidbeting pc- 
tential; 2) myccardial infarction within 3 months of screening; 
3) history of lie-threatening events associated with previous 
episodes of coronary artery spasm, such as veniricular tachy- 
cardia, ventricular fibrillation or syncoptd episodes; 4) decom- 
pensated congestive heart failure; 5) significant valvular heart 
disease; 6) systolic blood pressure < IMJ mm Hg or diastolic 
blwd orewre ,100 mm He: 7) life-threatenine arrhvthmias: 
8) EC6 abnormalities preclu;i/n~ interpretation if ST changes; 
9) concomitant use of another investigational drug or cardiac 
glycoside; 10, coronary artery bypass surgery orpxutaneour 
tclnsluminal corcmary angioplasty within 3 months of screen- 
ing; II) active hepatic or renal disease; and 12) other major 
concomitant disease. 
All patients provided written informed consent. The 
protocol was approved by the institutional Review Boards of 
?!I participating centers. 
Study Prorocol 
Double-blind trial. The studv desian (Fig. 1) included a 
period of a single-blind placebo III& (3 to I4 days) after 
withdrawal of coronary vasodilators (calcium channel block- 
ers or lowactinl! nitrates). Patients were allowed onlv 
sublingual &oglyierin as needed for episodes of chest pain. 
Patients were entered into the double-blind phase of the 
study after developing a minimum of three episodes of 
angina at rest. The single-blind placebo run-in period was 
designed to last 2 weeks but could he shortened as needed to 
a minimum of 3 days if patients had such a severe Rare-up of 
their anginal syndrome that they were unlikely to tolerate it 
for the $112 weeks. 
of the coronary spasm and at least three anginaI attacks 
during the single-blind placebo run-in period, they were 
randomized according to a parallel design to receive either 
amlodipine (IO mg) or placebo every morning. The double- 
blind parallel period lasted 4 weeks, with patients coming for 
follow-up visits at weekly intervals. An angisa diary for 
detailing the frequency, severity, duration and circum- 
stances of angina1 episodes and intake of sublingual nitro- 
glycerin was given to the patient at the initiation ofthe run-in 
wriod. Contents of the diaries were reviewed and tabulated 
at weekly intervals. Safety was monitored by clinical evalu- 
ation, with wessmeot for ooy side effects at ash visit and 
laboratory tests at baseline and at the end of the double-bli1.r 
period. Premature termination of the study was considered if 
the patient had a major adverse cxparience or evidence of 
therapeutic failure. defined as significant worsening of the 
angieal syndrome resulting in intolerable symptoms or ad- 
mission to the hospital to role out myocardial infarction. 
Open labei extenrion. Patients who completed the double- 
blind phase as raponders to nmlodipine were offered the 
option to continue treatment in an open label long-term 
protocol. Also, patients who completed the short-term pla- 
cebo phase with unchanged or worsened symptoms were 
offered the option of undergoing an open label trial of 
amlcdipine. Placebo responders were not entered into the 
long-term study. All patients in the open label long-term 
protocol were followed up for efficacy and safety with visits 
at 4week intervals for the 1st 2 months and every 3 months 
thereafter for up to 3 years. Adjustment of amlodipine 
dosage to 5 or l<mg daily, depending on clinical status, was 
allowed as needed during this phase of the study. 
Strdttcs. The diary&rived variables (rate of angina 
attacks and nitroglycerin consumption) were analyzed by the 
Wilcoxon rank-sum test using the final baseline diUennce in 
median values (the data were not normally distributed). 
In addition, the data on rate of angina1 episodes (Fig. 2) 
Once a patient qualified for the study with documentation were analyzed by analysis of vmiaoce, using the change 
from baseline (square root transformed). This adjustment for 
baseline values was made because the baseline rate of 
angina1 episodes and nitroglycerin use was higher m rhe 
amlodipine-treated patients than in the placebo-treated 
group. However, the difference between the two groups was 
not statistically significant at baseline. 
The therapeutic failure rate (discontmuation of treatment 
because of lack of efficacy) was subjected to logistic regres- 
sion analysis with the baseline rate of anginal episodes as 
covariate. 
Results 
Fifty-two patients with well documented vasospastic an- 
gina entered the study. Twenty-four pntients were mndom- 
ized lo receive amlodipine and 28 to receive placebo. The 
two treatment groups were comparable with regard to age. 
gender, severity of angina at baseline and history of previous 
myowdial infarction (Table I). Coronary angiography data 
near the time of randomization were available for44 patients 
and showed comparable findings in both croups (Table 2). 
The qualifying spasm occurred dming these &dies in 38 
patients. and in 14 patients (7 receivinp. amlodioine and 7 
&eiving placebo). ~coronary spasm was dca&ted by 
indirect(ECG or thallium-201 scintignphy) criteria. Efficacy 
(anginal attack rate) was analyzed from data for 50 patients 
(23 receiving amlodipine and 27 receiving placebo). Two 
Figure 3. Courw of weekly anginal episudcr in the two groups. 
Each point rep~~ents a group mean value. Week 0 is lawline; 
weeks I. 2. 3 and 4 are during double-blind therapy. 
patients lone from each treatment group) did not hwe valid 
analyzable dam. Efficacy das fc: zit~~jycerin consumption 
were available for analysis from 48 patients (22 receiving 
amiodipme and 26 receiving placebo). 
.Anginal episode rate. The rate of anginal episodes de- 
creased significantly (p = 0.009) during amlodipise therapy 
complrpd with the nte during placebo treatment (Fii. 2) and 
the improvement with amlodipine was consistent hroughout 
the 4.week study period (Fig. 3). Nitroglycerin intake 
showed a similar trend, but the difference failed TV attain 
statistical significance (Fig. 4). 
‘Therapeutic failure. Two of 24 patients receiving amlo- 
dipine were withdrawn from the study because of thempeu- 
Figure 4. The course of nitroglycerin (NTG) [able, consumpdon i  
the two groups. Exh point represents a group mean value. Week 0 
is basehne: weeks I, 2, 3 and 4 are during double-blind therapy. 
Figure 5. The percent of patients in the two groups (b&m row) 
who discontinued therapy because of therapeutic failure Clack of 
efficacy).The numberofpltientswhodiscontinuEdand rhenumber 
of patients in each group are shown in parentheses. Logistic 
regression analysis fwlred in p = 0.055 for between-group differ- 
tic failure (I patient because of admission to the hospita! to 
rule out myocardial infarction and I BF arerxlt ofpersistent 
inroieiable angina). Seven of 28 patients receiving placebo 
were withdrawn for the same reason (lack of efficacy). 
Regression analysis of these data showed that the probability 
of discontinuations for lack of e0icacy was higher with 
placebo than with amladipine therapy, regardless of baseline 
severity of angina. However, the difference was only mar- 
ginally significant (p = 0.055, Fii. 5). 
Hemadyoamic effects. The administration of amlodipine 
had no significant effect on supine or standing heart rate or 
supine or standing systolic and diastolic blood pressure. The 
results of administration of amlodipine and placebo are 
shown in Table 3. 
Adverse -actions. Adverse reactions (side effects) are 
presented in Table 4. The only side effect clearly more 
common with amlodipine than with placebo was peripheral 
edema. No patient was withdrawn from the double-blind 
phase of the protocol because of an adverse reaction. 
Lang-term opn label protoeoal. Twenty-nine patients en- 
tered the long-term open label protocol and 20 were continu- 
ing in this protocol at 1 year. Data on anginaI episodes and 
Tahte 4. Side EiTects in 51 Study Patients 
nitroglycerin consumption were obtained from 17 and 19 
patients, respectively (Fig. 6, A and B). 
The mean frequency of angina was 1.6 episodes/day at 
baseline and decreased significantly to 0.1 episodedday at 
i year (p = 04094, Fig. 6A). The mean baseline nitroglycerin 
intake was I.3 tablets/week and significantly decreased to 
0.2 tablet/week at I year (Fig. 68) 
The adverse reaction profile with one exception was 
similar to the short-term pattern. consisting of infrequent 
and mild side effects. The exception WE peripheral edema, 
which wasnoted more frequently (I2 of29patients), with the 
increase usually attributable to increased dosage. The edema 
was mostly mild and well tolerated and improved in most 
cases with or without reduction in the maintenance dose. 
Only one patient was withdrawn from the long-term trial 
because of a side e5ect (prwitus). Eight other patients were 
withdrawn for various administrative reasons related mostly 
to impracticality of follow-op. 
DiSCUSSfOlI 
Verapamil. the first clinically useful calcium channel 
blocker, and nifedipine, the first dihydropyridine derivative, 
were synthesized in Germany in the early 19&X. However, it 
was IO to IS years later before they received any significant 
‘Fable 3. EWcts on Blood Pressure and Heul Rate 
design clearly afforded an opportunity toc~ttkimt the relative 
frequency of such episodes. Nevertheless, the decrease in 
frequency of angina was sigttiticmttly greater with amlo- 
dipioe than with placebo and the response was consistent 
throughout the duuble-blind period (Fig. 3). Funhermorc, 
the rate of withdrawal from treatment was lower in patients 
rccciring amlodipine (Fig. 5). In addition, the two patients 
receiving amlodipine who were withdrawn imm the study 
had been previously treated uwuccessfuUy with several 
commercially available calcium cbatmel blockers. The long- 
term study provided further support for the efficacy of 
amlodipine. with a marked decrease in frequency of angina 
and nitroglycenn intake fmm baseline (Fig. 6). 
The hemodynamic &ects of ambdipine were minimal 
and insignificant (Table 2). Althou& amlodipine is an effcc- 
five antihypertensive agettt (24). there were no sigttiicant 
effectson blood pressureinournormotensivepbnts. Also. 
the lack of sigr&x: tacbyiaitiiac response IO aml&ipine 
cmtstitutes an advantage of this agent over older dihydro- 
pyridine derivatives (B-27). The itpparent absence of a 
tachycardiac response in healthy volunteen and hypa’ten- 
sive patients is attributed to the gradual unset of action of 
F@trc 6. Results of the long-term open label study. A, hlean rate ? 
SEM ofdaily anginai episodes at baseline and final assessment (n = 
17). 8. Mean + SEM daily consumption of nitroglycerin tablets at 
baseline and final assessment (n = 1% 
attention in the United States. The lint real notice of these 
agems was probably the result of their potential value in the 
weatment of coronary artery spasm (21). Nevenhe!ess. only 
a few studies (15.22) evaluated newer calcium channel 
blockers in patients with vasospastic at&a. rc:!taps in part 
because of the diicttll~ in recntitillg patients for such 
studies. It is well recognized that patie% with vasu,pastic 
angina today may receive effective therapy by a primary care 
physician withwt any documentation of the vasospasm. A 
good number of these patients may never report to a 
cardiologist, let alone to a research cardiology group in a 
major medical center. Thus. an investigator studying 
spasm may have access to fewer potential candidates and 
many ofthese may be patients who I) have shown resistance 
to the commercially available calcium channel blockers. or 
2) present diwtostic difficulties because cf atypical features 
&I may have L less predictable cwrse thanthat of mere 
typical patients. The freqwncy of spontaneous remission 
(23). which complicates therapeutic assessment. particularly 
when placeb~ontrolled trials are attempted, presents an- 
other impediment to such studies. 
In the cttrrent trial. we successfully m&ted patients at 
IS cemers. Fifty-two patients with well documented vaso- 
spastic an&ta were entered. with SO patients fully satisfying 
the &id protocol and producing analyzable data that showed 
statistically significant differences in end points. 
Although this study was not designed to survey or con- 
litm the frequency of spontaneous remissions. the parallel 
amlodipine (27). 
This study also detttottstrates that amladipine is P safe 
product with infrequent and mild side effects. The only 
significant side effect clearly more frequent than with pla- 
cebo was pedal edema. This Symptom Seemed to be related 
to the dose of amlodipine used and tended to lessen with 
dose adjustments and someumes with time while the same 
dose w& cominued. No patient had to be withdrawn iium 
the study because of edema. The only withdrawal was the 
result of pruritus. which was relieved promptly after discon- 
tinuation of amlodipine. 
Conchtsions. This study suggests that amlodipine ir effii- 
cacious and safe in the treatmettt of vasospaslic anpitm. Its 
convenient once a day dosage and hemodynamic and safety 
profile may conttibute to making it a potcniial agent of 
choice in vasospastic angina. 
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